Health
New experimental pill shows major promise in treating advanced pancreatic cancer
Reported by Rituparna Sen (Section Editor) Β· Indian Express - Health Β·
Confirmed by a second source: BBC News - Health

An experimental daily pill called daraxonrasib has stopped tumour growth in 90 per cent of trial participants with advanced pancreatic cancer that had spread to other organs.
Trial Results And Survival
In the trial of 61 patients, tumours shrank or disappeared in over 60 per cent of participants, while roughly 8 per cent had tumours that became undetectable on CT scans. About 76.6 per cent of patients were alive a year after starting treatment, compared to the usual 40 to 45 per cent survival rate with chemotherapy alone. The trial followed patients for an average of a year and a half, with some seeing no cancer return during that time. Dr Wungki Park from the Memorial Sloan Kettering Cancer Center noted that the results show deeper responses and a near-doubling in the duration of disease control.
How The Drug Works
Most pancreatic cancers carry alterations in the KRAS or RAS gene that send signals for cancer cells to grow. Daraxonrasib is a targeted inhibitor that blocks these faulty signals and shuts off the specific mutations driving tumour growth. Dr Parveen Jain, Senior Consultant and HOD for Medical Oncology at Aakash Healthcare, notes that the drug targets the mechanism sustaining the tumour itself rather than fast-dividing cells like conventional chemotherapy does. Cancer Research UK described the findings as the biggest leap forward for pancreatic cancer patients in decades, with Dr Sam Godfrey stating that the drug has found a way to drug the undruggable.
Caution And Next Steps
Researchers and doctors stress that the drug is not yet a cure, as scans cannot detect individual or clumps of remaining cancer cells that could cause the disease to return. Dr Jain also noted that the study was small and used historical comparisons rather than randomised groups, meaning larger phase III trials are needed to prove it improves overall survival. Subsequent trials are also testing daraxonrasib in combination with chemotherapy drugs such as gemcitabine and nab-paclitaxel.
Context
Pancreatic cancer has one of the lowest survival rates of all common cancers because it is notoriously hard to treat and tends to spread to other organs early. Because many other cancers like lung and ovarian tumours also carry similar RAS mutations, successful treatments developed for pancreatic cancer could potentially help patients with other forms of the disease.
ExplainerWhy this matters
What Happened
An experimental daily pill called daraxonrasib was tested on 61 patients with advanced pancreatic cancer, resulting in stopped tumour growth in 90 per cent of participants and undetectable tumours on scans for about 8 per cent.
Why It Matters
Pancreatic cancer has historically had the lowest survival rate among common cancers because standard chemotherapy struggles to stop its progression. Because daraxonrasib specifically targets the RAS gene mutations that drive tumour growth rather than attacking all fast-dividing cells, it represents a major breakthrough that could also eventually apply to other mutation-driven cancers like lung and ovarian cancer.
What Happens Next
Researchers must conduct larger phase III randomised trials and longer-term studies to confirm whether the drug genuinely improves overall survival, prevents cancer from returning, and proves safe for routine clinical use.
More in Health
HealthVerified β Confirmed by a second source: Bing News - Health (India)Important
New Study Urges Community-Led Mental Health Care for Refugees in India
Reported by Kavya Rao (Senior Writer) Β· The Hindu - Health Β·
HealthVerified β Confirmed by a second source: Google News - USA HealthImportant
Child Death Reported in Virginia as National Measles Cases Rise.
Reported by Ishita Mukherjee (Staff Writer) Β· The Hindu - Health Β·
HealthVerified β Confirmed by a second source: Bing News - Health (India)Important
Insurance Regulator Fines Star Health Two Crores Over Claim Rules.
Reported by Vivek Joshi (Copy Editor) Β· The Hindu - Health Β·
